HCW BIOLOGICS INC (HCWB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.94+2.44%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HCWB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -82.3% |
| Our one-year growth estimate | diamond | 100.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 182.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
HCWB — legal / regulatory event — Non-Reliance on Previously Issued Financial Statements or a Related Audit Rep…
Dated 2026-08-14
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. On August 10, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of HCW Biologics Inc. (the “Company”), in consultation with management and the Company’s independent registered public accounting firm, Crowe LLP, concluded that the Company’s previously issued unaudited condensed financial statements as of and for the three months ended March 31, 2026, included…
Why it matters: The FDA meeting will clarify the path for HCW11-018b's clinical trial. Positive feedback could speed up development.
Supportive ifFDA agrees on study needs for HCW11-018b. This lets the IND application move forward.
Worry ifFDA has big worries about the plan for HCW11-018b.
Why it matters: Staying compliant with Nasdaq is key for HCW Biologics. Non-compliance can hurt investor trust.
Worry ifThe company gets confirmation that it still meets Nasdaq listing rules.
Less concerning ifThe company does not meet Nasdaq rules, which could lead to delisting.
Why it matters: Regaining compliance with Nasdaq is important to keep the company's listing. Not complying could lead to delisting and hurt investor trust.
Worry ifNasdaq confirms HCW Biologics has regained compliance with the Bid Price Rule.
Less concerning ifNasdaq sends a notice of delisting due to ongoing non-compliance.
Why it matters: The full data readout will show if HCW9302 is effective for alopecia areata. Positive data could support future trials and partnerships.
Supportive ifThe full Phase 1 data shows big gains in SALT scores for patients using HCW9302.
Worry ifThe full data shows no big gains in SALT scores. No safety concerns came up.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$579 on $10,000 · ±5.8% | How much price usually moves either way. |
| Bad day | $1,640 loss on $10,000 · 16.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,521 loss on $10,000 · 95.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The full data readout will show if HCW9302 is safe and effective for alopecia areata. Good results could help with further development.
Supportive ifThe full Phase 1 human data readout is expected in Q4 2026. It will confirm safety and effectiveness.
Worry ifThe data readout shows no big changes in SALT scores or safety problems.
Why it matters: Ending the agreement could affect future partnerships and product plans.
Watch forThere is official word that the agreement has ended without problems.
Also watch forThere are reports of legal issues from the agreement ending.
Why it matters: This strategic move could impact future partnerships and revenue streams. Clarity on this will guide investor sentiment.
Watch forManagement shares news of new partnerships or licensing deals after the end.
Also watch forThere are no new partnerships. The termination hurts revenue.
Why it matters: Regaining compliance is key for HCW Biologics to avoid delisting. It impacts investor confidence.
Supportive ifManagement says Nasdaq compliance is kept for two months in a row.
Worry ifA new notice of delisting is issued by Nasdaq.
Why it matters: Commercializing HCW9206 could enhance revenue and partnerships in CAR-T therapies. This is crucial for growth.
Supportive ifThe company announces a deal for HCW9206. This will boost production and sales.
Worry ifNo deal is made, and HCW9206 stays uncommercialized.
Why it matters: Expanding licensing agreements can provide funding and support for HCW Biologics' clinical programs. It is key for growth.
Supportive ifHCW Biologics shares new licensing deals that help make more money.
Worry ifNo new licensing deals are announced. Current deals have problems.
Why it matters: New licensing deals can boost revenue and support growth. Progress here indicates the company's ability to expand its market presence.
Supportive ifThe company announces a new licensing deal that brings in at least $3 million upfront.
Worry ifThe company fails to secure any new licensing agreements in the next quarter.
Why it matters: Setting the Recommended Phase 2 Dose is crucial for advancing HCW9302 in clinical trials. It signals readiness for broader testing.
Supportive ifHCW9302 sets a Recommended Phase 2 Dose by the end of 2026. This supports more trials.
Worry ifThe company fails to establish a Recommended Phase 2 Dose by the end of 2026.